

The LFCS Consortium: 4 - Effect of formulation surfactants on the extent of in vitro digestion of a range of lipid-based formulations

Introducing the LFCS Consortium

The LFCS Consortium is a non-profit organization consisting of both academic and industrial partners with the overall objective of developing standardized in vitro tests for lipid-based formulations (LBFs). Work presented here details some of the experiments undertaken in the first year of the LFCS Consortium.

STUDY AIM: In the present poster, we present how the extent of lipolysis is affected by the type of surfactants.

LBFs are exposed to enzymatic digestion through the GI-tract, thus the impact of different formulation surfactants on the extent of digestion is of interest in LBF development.

Methods

- Table 1 below lists the composition of eight long-chain (LC) and medium-chain (MC) LBFs investigated within the LFCS. Formulations were incorporated with danazol at 80% of its solubility (37°C) in the pure formulation.
- Effect of pancreatin: One gram LBF (containing danazol) was initially dispersed in 36mL digestion medium (pH 6.5, 2mM trismaleate, 1.4mM calcium, 150mM NaCl, 3mM sodium taurodeoxycholate, 0.75mM phosphatidyl choline, 37 C) before digestion was commenced on addition of 4mL porcine pancreatin suspension (150, 300, 600 or 900 USP units/mL).
- Effect of calcium The initial calcium levels were varied (0, 1.4, 5, or 10mM) in a digestion medium (pH 6.5, 2mM tris-maleate, 150mM NaCl, 3mM sodium taurodeoxycholate, 0.75mM phosphatidyl choline, 37 C), and digestion was commenced on addition of 4mL porcine pancreatin suspension (600 USP units/mL)
- Digestion was continuously monitored using a pH-stat titrator (Titrando®, Metrohm). Particle size was measured with a Malvern Zetasizer ZS.

LBF type	Composition (% w/w)							
	Corn oil	Maisine [™] 35-1	Tween 85	Cremophor EL	Captex	Capmul	Transcutol	[
I-LC	50	50	-	-	-	-	-	
II-LC	32.5	32.5	35	-	-	-	-	
III-LC	32.5	32.5	-	35	-	-	-	
I-MC	-	-	-	-	50	50		
II-MC	-	-	35	-	32.5	32.5	-	
IIIA-MC	-	-	-	35	32.5	32.5	-	
IIIB-MC	-	-	-	50	-	25	25	
IV	-	-	-	50	-	-	50	

Table 1: Composition of the eight LBFs investigated by the LFCS Consortium





MONASH University







France. 6. Global Pharmaceutical Sciences, Capsugel, France. 7. Merck KGaA, Darmstadt, Germany.















